Table 1 Baseline characteristics and laboratory data for patients with and those without pre-existing statin use on the event of stroke
From: Statin therapy reduces oxidized low density lipoprotein level, a risk factor for stroke outcome
|  | Risk controls (n = 80) | Stroke patients (n = 120) | P- value |
|---|---|---|---|
Age, y, mean ± SD | 58.3 ± 10.7 | 60.2 ± 10.6 | 0.08 |
Sex male, % | 70.0 | 74.2 | 0.93 |
Hypertension, % | 50.0 | 72.5 | 0.12 |
Diabetes mellitus, % | 30.0 | 35.0 | 0.86 |
Hyperlipidemia, % | 36.3 | 47.5 | 0.12 |
White blood cells ×103/mL | 5.7 ± 2.0 | 7.6 ± 2.0 | <0.001 |
Red blood cells ×106/mL | 4.6 ± 0.4 | 4.8 ± 0.8 | 0.36 |
Platelet counts ×104/mL | 20.9 ± 5.8 | 21.2 ± 6.2 | 0.77 |
Total cholesterol, mg/dL | 182.1 ± 27.9 | 192.3 ± 38.8 | 0.16 |
LDL-cholesterol, mg/dL | 96.4 ± 27.1 | 119.1 ± 36.2 | 0.001 |
Triglyceride, mg/dL | 139.3 ± 90.1 | 141.7 ± 77.7 | 0.89 |
HbA1c, % | 6.8 ± 1.4 | 6.9 ± 2.1 | 0.73 |
Ox-LDL on admission, U/L | 25.9 ± 2.9 | 33.4 ± 3.0 | <0.001 |